Display options
Cite
Chen Y, Qiu Y, Fu H, et al. IgD multiple myeloma with central nervous system involvement: A case report and literature review. Mol Clin Oncol. 2021;15(4):198doi: 10.3892/mco.2021.2360.
Chen, Y., Qiu, Y., Fu, H., Li, J., Chen, L., Liao, S., & Liu, T. (2021). IgD multiple myeloma with central nervous system involvement: A case report and literature review. Molecular and clinical oncology, 15(4), 198. https://doi.org/10.3892/mco.2021.2360
Chen, Yi, et al. "IgD multiple myeloma with central nervous system involvement: A case report and literature review." Molecular and clinical oncology vol. 15,4 (2021): 198. doi: https://doi.org/10.3892/mco.2021.2360
Chen Y, Qiu Y, Fu H, Li J, Chen L, Liao S, Liu T. IgD multiple myeloma with central nervous system involvement: A case report and literature review. Mol Clin Oncol. 2021 Oct;15(4):198. doi: 10.3892/mco.2021.2360. Epub 2021 Aug 04. PMID: 34462654; PMCID: PMC8375031.
Copy Download .nbib Format: NLM
Share it on

Mol Clin Oncol. 2021 Oct;15(4):198. doi: 10.3892/mco.2021.2360. Epub 2021 Aug 04.

IgD multiple myeloma with central nervous system involvement: A case report and literature review.

Molecular and clinical oncology

Yi Chen, Yanyan Qiu, Haiying Fu, Jing Li, Lushan Chen, Siqin Liao, Tingbo Liu

Affiliations

  1. Fujian Provincial Key Laboratory on Haematology, Fujian Medical University Union Hospital, Fujian Institute of Haematology, Fuzhou, Fujian 350001, P.R. China.

PMID: 34462654 PMCID: PMC8375031 DOI: 10.3892/mco.2021.2360

Abstract

Central nervous system (CNS) involvement is a rare manifestation of multiple myeloma (MM) and the optimal management strategies have yet to be determined. The aim of the present study was to describe the case of a 47-year-old male patient with immunoglobulin D-λ MM who presented with multiple extramedullary infiltrations at diagnosis. This patient achieved stringent complete response after 9 cycles of treatment with bortezomib, lenalidomide and dexamethasone, and then received lenalidomide as maintenance therapy. CNS involvement and extramedullary relapse developed 3 months after the last chemotherapy cycle. Despite receiving a second-line treatment protocol, the patient succumbed to the disease within 1 month after recurrence. The characteristics and treatment options for CNS MM are discussed in this case report.

Copyright: © Chen et al.

Keywords: central nervous system; extramedullary; involvement; multiple myeloma

Conflict of interest statement

The authors declare that they have no competing interests.

References

  1. Eur J Haematol. 2008 Jan;80(1):1-9 - PubMed
  2. Br J Haematol. 2002 Apr;117(1):103-8 - PubMed
  3. Ann Hematol. 2015 Dec;94(12):2033-42 - PubMed
  4. Clin Case Rep. 2018 Mar 02;6(4):723-728 - PubMed
  5. Leukemia. 2020 Jan;34(1):1-20 - PubMed
  6. Haematologica. 2012 Nov;97(11):1761-7 - PubMed
  7. Blood Rev. 2019 Jul;36:32-39 - PubMed
  8. Leuk Lymphoma. 2004 Feb;45(2):291-300 - PubMed
  9. J Oncol. 2018 Apr 23;2018:3970169 - PubMed
  10. J Clin Oncol. 2015 Sep 10;33(26):2863-9 - PubMed
  11. Clin Lymphoma Myeloma Leuk. 2016 Nov;16(11):644-654 - PubMed
  12. Lancet Oncol. 2014 Nov;15(12):e538-48 - PubMed
  13. Rev Bras Hematol Hemoter. 2018 Jan - Mar;40(1):30-36 - PubMed
  14. Invest New Drugs. 2012 Dec;30(6):2303-17 - PubMed
  15. Blood Cancer J. 2014 Aug 15;4:e239 - PubMed
  16. Blood. 2016 Jun 2;127(22):2693-700 - PubMed
  17. Br J Haematol. 2017 Apr;177(2):221-225 - PubMed
  18. Blood. 2016 Jun 16;127(24):2955-62 - PubMed
  19. Haematologica. 2020 Jul;105(7):1780-1790 - PubMed
  20. Expert Opin Pharmacother. 2018 Mar;19(4):375-386 - PubMed
  21. Curr Cancer Drug Targets. 2017;17(9):846-857 - PubMed
  22. N Engl J Med. 2011 Mar 17;364(11):1046-60 - PubMed

Publication Types